Published in Nat Rev Clin Oncol on February 16, 2016
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
High drug attrition rates--where are we going wrong? Nat Rev Clin Oncol (2011) 5.67
Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol (2010) 1.13
Gastrointestinal cancer: a step closer to combating acquired resistance in CRC. Nat Rev Clin Oncol (2012) 1.05
Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2010) 0.93
Personalized cancer medicine: era of promise and progress. Nat Rev Clin Oncol (2011) 0.84
Oncology trials--the elephant in the room. Nat Rev Clin Oncol (2012) 0.84
Biomarkers: ctDNA-identifying cancer before it is clinically detectable. Nat Rev Clin Oncol (2015) 0.82
Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer. Nat Rev Clin Oncol (2015) 0.82
Genetics: tracking clonal origin of prostate cancer. Nat Rev Clin Oncol (2013) 0.81
Patients with high-risk aPl benefit from risk-adapted consolidation therapy. Nat Rev Clin Oncol (2010) 0.81
Skin cancer. Golden age of melanoma therapy. Nat Rev Clin Oncol (2014) 0.81
Digital infrared breast scan shows promise for detecting cancer. Nat Rev Clin Oncol (2010) 0.80
Palliative care: benefits of Liverpool Care Pathway. Nat Rev Clin Oncol (2013) 0.79
Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib. Nat Rev Clin Oncol (2010) 0.79
Breast cancer: ALTTO: wake-up call for setting up clinical trials. Nat Rev Clin Oncol (2013) 0.79
Skin cancer: less is as good as more in refractory melanoma. Nat Rev Clin Oncol (2014) 0.79
Herceptin: HERalding a new era in breast cancer care but at what cost? Nat Clin Pract Oncol (2005) 0.79
Lung cancer: Squiring immunotherapy to CheckMate. Nat Rev Clin Oncol (2015) 0.78
Genetics: predictor for prostate cancer. Nat Rev Clin Oncol (2011) 0.78
Skin cancer: Novel resistance mechanism revealed. Nat Rev Clin Oncol (2011) 0.78
Screening: BRCA testing in women younger than 50 with triple-negative breast cancer is cost effective. Nat Rev Clin Oncol (2010) 0.78
Immunotherapy: Evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol (2015) 0.77
Screening: CT screening for lung cancer: winner confirmed. Nat Rev Clin Oncol (2013) 0.77
Radiotherapy: Repopulating tumor cells--dying for caspase 3. Nat Rev Clin Oncol (2011) 0.77
Liver cancer: sorafenib resistance uncovered by novel RNAi screen. Nat Rev Clin Oncol (2014) 0.77
Targeted therapies: LUX-Lung trials-not all mutations are created equal. Nat Rev Clin Oncol (2015) 0.76
Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors. Nat Rev Clin Oncol (2010) 0.76
The era of personalized medicine: back to basics. Nat Clin Pract Oncol (2008) 0.76
Radiotherapy: DNA repair--a marker of late toxicity. Nat Rev Clin Oncol (2014) 0.76
Focus issue on biomarkers. Nat Rev Clin Oncol (2010) 0.76
Immunotherapy: Clonal neoantigens and immune response: a balancing act. Nat Rev Clin Oncol (2016) 0.76
Radiotherapy: abscopal responses: pro-immunogenic effects of radiotherapy. Nat Rev Clin Oncol (2015) 0.76
New paradigms to explain metastasis. Nat Rev Clin Oncol (2011) 0.76
Immunotherapy: Harmonizing the immune response with a cancer vaccine. Nat Rev Clin Oncol (2012) 0.76
Prevention: MAPping out breast cancer chemoprevention. Nat Rev Clin Oncol (2011) 0.76
Screening: Where does stool DNA testing FIT in the CRC screening menu? Nat Rev Clin Oncol (2014) 0.76
Closing the controversies gap in prostate cancer? Nat Rev Clin Oncol (2014) 0.75
Palliative care. Chemotherapy and hope of cancer cure: dying expectations. Nat Rev Clin Oncol (2012) 0.75
Immunotherapy: Novel approach for universal adoptive cell transfer therapy with improved outcome. Nat Rev Clin Oncol (2011) 0.75
Drug therapy: a new standard for thyroid cancer? Nat Rev Clin Oncol (2011) 0.75
Combination therapies: New prognostic factor for brain metastasis from ovarian cancer. Nat Rev Clin Oncol (2011) 0.75
Risk factors: Cachexia--skeletal muscle depletion is a prognostic factor. Nat Rev Clin Oncol (2013) 0.75
Genetics: New miRNA classifier distinguishes CTCL from benign skin disorders. Nat Rev Clin Oncol (2011) 0.75
Imaging: PET is prognostic of survival in pancreatic cancer patients. Nat Rev Clin Oncol (2010) 0.75
Human CML stem cells insensitive to imatinib even when BCR–ABL is inhibited. Nat Rev Clin Oncol (2011) 0.75
Hematology: cast iron results for ESA use in cancer. Nat Rev Clin Oncol (2011) 0.75
Breast cancer: Risk of death not increased for patients with dense breasts. Nat Rev Clin Oncol (2012) 0.75
Colorectal cancer: A step closer to combating acquired resistance in CRC. Nat Rev Gastroenterol Hepatol (2012) 0.75
Gynecological cancer: True progress in ovarian cancer or just the tip of the iceberg? Nat Rev Clin Oncol (2012) 0.75
Targeted therapies: the answer to individualized treatment? Nat Clin Pract Oncol (2007) 0.75
Screening: Reduced breast cancer mortality rates in Europe are not due to screening. Nat Rev Clin Oncol (2011) 0.75
SSP reliability for breast cancer. Nat Rev Clin Oncol (2010) 0.75
Immunotherapy. Relapse-tuning the microenvironment. Nat Rev Clin Oncol (2012) 0.75
Breast cancer: Radiation risk in BRCA carriers. Nat Rev Clin Oncol (2012) 0.75
Immunotherapy: Alphavirus vector induces immune response in advanced cancers. Nat Rev Clin Oncol (2010) 0.75
Urological cancer: Genetic landscape studies of prostate cancer offer new clues. Nat Rev Clin Oncol (2012) 0.75
Prevention: long-term benefits of tamoxifen. Nat Rev Clin Oncol (2011) 0.75
Chemotherapy: DNA repair predicts survival in patients with NSCLC. Nat Rev Clin Oncol (2011) 0.75
Urological cancer: TKIs strike back: complete remission in kidney cancer. Nat Rev Clin Oncol (2012) 0.75
Breast cancer: Fewer therapy cycles is better. Nat Rev Clin Oncol (2012) 0.75
Lenalidomide for multiple myeloma. Nat Rev Clin Oncol (2010) 0.75
Hematology: Allografting offers better outcomes than autografting for patients with myeloma. Nat Rev Clin Oncol (2011) 0.75
Screening: Improved model for lung cancer detection. Nat Rev Clin Oncol (2013) 0.75
Immunotherapy. Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine. Nat Rev Clin Oncol (2010) 0.75
Hematology. Poor outcome to induction therapy for nonresponders. Nat Rev Clin Oncol (2010) 0.75
Genetics: BRCA2 mutation offers response and survival advantages. Nat Rev Clin Oncol (2011) 0.75
Treatment modalities: HIFU is effective for unresectable HCC. Nat Rev Clin Oncol (2011) 0.75
Lung cancer: OPTIMAL results for erlotinib in NSCLC. Nat Rev Clin Oncol (2013) 0.75
Hematology. Allo SCT offers hope as second-line therapy for CML. Nat Rev Clin Oncol (2010) 0.75
Urological cancer: Radical lessons learnt from the prostate cancer PIVOT trial. Nat Rev Clin Oncol (2012) 0.75
EPIC risk: behind the smoke-screen. Nat Rev Clin Oncol (2012) 0.75
Chemotherapy: Cisplatin more effective when given less often. Nat Rev Clin Oncol (2011) 0.75
Haematological cancer: For elderly, R-CHOP and maintain. Nat Rev Clin Oncol (2012) 0.75
Targeted therapies: Progress for KRAS mutant NSCLC. Nat Rev Clin Oncol (2012) 0.75
Chemotherapy: Killing vessels improves delivery. Nat Rev Clin Oncol (2011) 0.75
Palliative care: Analgesia prescribing in the USA--no gain, much pain. Nat Rev Clin Oncol (2012) 0.75
Breast cancer: Genetic signature trumps clinicopathological features. Nat Rev Clin Oncol (2013) 0.75
Haematological cancer: Less is more for paediatric patients--it's ALL in the dosing. Nat Rev Clin Oncol (2012) 0.75
Chemotherapy: final ACT for standard of care in anal cancer? Nat Rev Clin Oncol (2013) 0.75
Radiotherapy: avoiding EBRT for those without high-risk endometrial cancer. Nat Rev Clin Oncol (2011) 0.75
Gynaecological cancer: CLOVAR validates prognostic gene-expression signature. Nat Rev Clin Oncol (2013) 0.75
Patient profiling in breast cancer--is knowledge power? Nat Rev Clin Oncol (2011) 0.75
Hematology: New hope for lymphoma patients. Nat Rev Clin Oncol (2011) 0.75
Last 30 days--hitting too hard? Nat Rev Clin Oncol (2012) 0.75
Gastrointestinal cancer: Less is more for surgical treatment of oesophageal cancer. Nat Rev Clin Oncol (2012) 0.75
Haematological cancer: Better survival, toxicity no worse. Nat Rev Clin Oncol (2012) 0.75
Gastrointestinal cancer: Screening cost effective, not treatment. Nat Rev Clin Oncol (2012) 0.75
Medical oncology: Letrozole efficacy confirmed. Nat Rev Clin Oncol (2011) 0.75
Targeted therapies: Radiopeptide therapy improves outcomes for neuroendocrine cancers. Nat Rev Clin Oncol (2011) 0.75
Targeted therapies: bevacizumab and chemotherapy do not increase the risk of VTEs. Nat Rev Clin Oncol (2011) 0.75
Hematology: NK gene donor selection in AML. Nat Rev Clin Oncol (2011) 0.75
Bladder cancer: Gene-expression signature in urine indicates aggressive disease. Nat Rev Urol (2010) 0.75
Hematology: Rituximab improves survival for solid organ transplant recipients with PTLD. Nat Rev Clin Oncol (2010) 0.75
Skin cancer: Novel mouse model reveals strategy to delay drug resistance in melanoma. Nat Rev Clin Oncol (2013) 0.75
Targeted therapies: Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma. Nat Rev Clin Oncol (2011) 0.75
CLL pathogenesis: novel microRNA/ TP53 feedback circuitry. Nat Rev Clin Oncol (2011) 0.75
Diagnosis: Gene-expression signature in urine diagnoses aggressive bladder cancer. Nat Rev Clin Oncol (2010) 0.75
Gastrointestinal cancer: Not all CRC subtypes are created equal. Nat Rev Clin Oncol (2012) 0.75
Laparoscopic rectal cancer surgery is safe and effective. Nat Rev Clin Oncol (2010) 0.75
Epidemiology: Triggering a bad stimulation. Nat Rev Clin Oncol (2011) 0.75